Brain Cancer Clinical Trials in North Carolina

Showing 161-177 of 177 trials

Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

NCT00093613

This phase I trial is studying the side effects and best dose of sorafenib in treating patients with recurrent or progressive malignant glioma. Sorafenib may stop the growth of tumor cells by stopping blood flow to the tumor and by blocking the enzymes necessary for their growth.

Adult Anaplastic AstrocytomaAdult Anaplastic OligodendrogliomaAdult Giant Cell Glioblastoma+2 more

National Cancer Institute (NCI)47 participantsStarted Dec 2004

Birmingham, Alabama, United States • Tampa, Florida, United States • Atlanta, Georgia, United States +7 more locations

WITHDRAWNPhase 341 miles

XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

NCT00226668

The purpose of this study is to examine the safety and efficacy of XERECEPT (human Corticotropin-Releasing Factor, or hCRF) compared to dexamethasone in patients with primary malignant glioma who require increased dexamethasone doses to control symptom of peritumoral brain edema.

Brain EdemaBrain Tumor

Celtic Pharma Development Services120 participantsStarted Jan 2006

Phoenix, Arizona, United States • La Jolla, California, United States • Newport Beach, California, United States +23 more locations

Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

Brain Cancer Trials in Other Cities

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors

Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors

Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma

A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma

Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)

IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma

Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme

Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse

A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas

Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients

Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer

Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors

Other Conditions in North Carolina